Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152301 | 0.89 | ADORA2A (0.55) | ADORA2AADORA2BADORA3RXFP1TMEM97 | |
| SCHEMBL4160361 | 0.85 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1HSP90B1 | |
| SCHEMBL4148702 | 0.83 | ADORA2A (0.57) | ADORA2AADORA2BADORA3RXFP1 | |
| SCHEMBL4231078 | 0.81 | ADORA2A (0.56) | ADORA2AADORA2BADORA3 | |
| SCHEMBL4231106 | 0.81 | ADORA2A (0.56) | ADORA2AADORA2BADORA3 | |
| SCHEMBL3876664 | 0.81 | ADORA2A (0.71) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4236084 | 0.81 | ADORA2A (0.71) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL4159761 | 0.81 | ADORA2A (0.52) | ADORA2AADORA2BADORA3RXFP1 | |
| Water SCHEMBL4239095 | 0.81 | ADORA2A (0.55) | ADORA2AADORA2BADORA3 | |
| Water SCHEMBL4239105 | 0.81 | ADORA2A (0.55) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | ADORA2A 33/4885ADORA2B 46/4885ADORA3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.